The Rise of Biotech: Examining Moderna’s Post-Pandemic Prospects

The biotechnology industry has seen an unparalleled boom following the COVID-19 disease, with companies such as Moderna spearheading this charge.

Moderna has become a household name in the world, known primarily for its quick development and deployment of mRNA-1273 COVID- 19 vaccine as an embodiment of hope and scientific revolution.

However, as the acute phase of the pandemic wanes, the question arises: What is the future for Moderna in a world beyond COVID-19?

Read More: This Biotech Company Could be a Hidden Gem

Moderna Biotech Company – Project Portfolio

Moderna is constantly broadening its research and development beyond the COVID-19 vaccine, exploring various other projects that utilize their groundbreaking mRNA technology.

As per conversations with the CEO of Moderna, Stéphane Bancel, it has been possible for this company to quickly adapt its mRNA platform in response to COVID-19 pandemic showing that such a platform is flexible and rapid enough at developing vaccines which are effective.

This flexibility has now been directed towards the creation of vaccines for other infectious diseases such as RSV (respiratory syncytial virus), HIV, Zika and Epstein-Barr Virus thus demonstrating that mRNA technology can address a wide range of health concerns​.

Moreover, the fate of mRNA vaccines seems to be bright since there are high expectations for a flu vaccine capable of providing universal protection against various strains.

The flu vaccine of the company, mRNA-1010 has demonstrated promising data in phase 3 trials and it is predicted that this product will be more efficient than currently available on market vaccines.

On the other hand, the mRNA-1345 RSV vaccine from Moderna is moving quickly through clinical trials. This shift into other vaccine segments shows that Moderna is looking to use its mRNA technology platform in treating a wider range of infectious diseases.

Opportunities and Challenges

The Moderna biotech company is at a crossroads following the Covid-19 pandemic and an influx of potential as well as challenges.

The unprecedented success of its COVID-19 vaccine did not only enable the company to have a huge amount of finance but also gave it an international platform for future R&D.

First, the pipeline that is currently in place with Moderna is flooded by potential vaccines for influenza RSV and Zika as well as more ambitious projects to combat cancer or rare genetic disorders.

Looking ahead, the adaptability of mRNA technology places Moderna to perhaps transform virtually every health problem from preventative measures into curative solutions and entering an age that will be dominated by medicine.

The post-pandemic biotech industry journey for Moderna is characterized by a deliberate change in the route towards diversification and product pipeline management as well as manufacturing issues.

Moderna capitalizes on the remarkable success of their mRNA-1273 COVID -19 vaccine by using its technology platform for diseases beyond those caused by coronavirus such as cancer.

The company collaborates with Big Pharma, including Merck & Co., to create personalized cancer vaccines such as mRNA-4157 which are about to enter the third phase of clinical trials.

This cooperative process is meant to create creative cancer treatment modalities but not without challenges of manufacturing complexities as that seen in the CAR-T therapy space.

Highly customized medicine is prone to unforeseen complications in manufacturing, as specialized production is required for each patient’s tumor profile, increasing the probability of operational bottlenecks.

Also Read: The 4 Largest Stock Exchanges in the World and the Pros and Cons of Each

Scalability and Viability

Scaling of production and distribution for new products is one the focal points in Moderna’s future strategy. Logistically speaking, the company has shown its prowess in speeding up and distributing of COVID-19 vaccines all over the world.

Nevertheless, copying this triumph for a broader array of products is no easy task because it requires maneuvering through the challenging terrain that consists of strategic partnerships, manufacturing infrastructure and supply chains.

Moderna’s experience during the pandemic with executive decision making that had to be rapid and being able to adjust quickly enough for a global health crisis is what has prepared it for these challenges.

The decentralized nature of this company’s structure ensured flexibility and mobility, which is critical for scaling production.

Furthermore, the supply chain strategy that facilitated rapid deployment of COVID-19 vaccine entailed a huge scale up in production involving an intricate network for new and existing suppliers to provide raw materials, logistics resources and cooling units.

Such complex coordination was also observed in distribution hubs, emergency vaccination centers and hospitals.

Obviously, the change in priorities of the supply chain automatically affects other drugs manufacturing now, especially those that require similar raw materials or temperature-controlled storage.

Financial Outlook

Financially, the Moderna biotech company is facing a terrain that has reduced demand for COVID-19 vaccine with strategic investments and partnerships to drive growth in new therapeutic areas.

Although COVID-19 vaccine revenue saw a decline, with Q4 sales of $ 4.8 billion falling from the previous year’s number; Moderna is determined to reinvest in its core mRNA platform for diseases such as influenza and latent infection.

The company is also seeking external investment avenues and has already ventured into massive collaborations and acquisitions to strengthen its R&D capacities. This also involves collaborations with firms such as CytomX and

Personalis, its first M&A deal in which OriCiro was acquired for $85 million. These tactical moves reflect Moderna’s desire to go beyond the pandemic and explore more technological, therapeutic spaces which are not without their own set of challenges regarding manufacturing capacity and market demand.​

Ethical Considerations

Moderna has taken active measures to ensure that ethical and equitable distribution is maintained to address global health inequalities, especially during the COVID-19 pandemic.

First, Moderna committed to a nonenforcement of COVID-19 related patents during the pandemic period for wider vaccine production.

The company further pledged to provide up to 500 million doses for the COVAX Facility targeting lower-income countries and facilitated over 50 million through COVAX by September of last year.

A critical step towards the long-term healthcare solution in regions facing vaccine inequity is Moderna’s plans to establish an mRNA facility in Africa that will produce up to 500 million doses annually.

Additionally, the Moderna biotech company is increasing its capacity to provide 1 billion doses more in low-income countries for the year 2022.

However, despite these initiatives’ challenges remain with some shareholders and health experts calling for more aggressive actions to achieve global vaccine equity highlighting issues related to pricing as well allocation of doses in low-income countries.

This need to tackle these gaps is further accentuated by the fact that such variants as Omicron spread so easily, a clear sign of global interdependence in terms of health.

Moderna Biotech – A Success?

Moderna is leading a biotech revolution driven by the pandemic. Its future after the pandemic looks bright because of innovative technologies, steady pipeline and good financial standing.

However, the road forward is complex, requiring creative approaches and efficacious solutions that can be scaled-up with a commitment to global health equity.

This landscape will not only determine its own fate but also the future of biotechnology and healthcare.

Read Next: 8 Stock Picks Morgan Stanley Recommends for 2024